Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
Locally advanced basal cell carcinoma (laBCC) remains a significant management challenge. Historically, surgery or radiotherapy represented the major treatment options. Recently, hedgehog inhibitors and checkpoint inhibitors have demonstrated significant activity. The optimal sequencing of these app...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1500785/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582022082592768 |
|---|---|
| author | Chalette Lambert-Swainston Wolfram Samlowski Wolfram Samlowski Wolfram Samlowski Brandon Reynolds Amin Hedayat Amin Hedayat |
| author_facet | Chalette Lambert-Swainston Wolfram Samlowski Wolfram Samlowski Wolfram Samlowski Brandon Reynolds Amin Hedayat Amin Hedayat |
| author_sort | Chalette Lambert-Swainston |
| collection | DOAJ |
| description | Locally advanced basal cell carcinoma (laBCC) remains a significant management challenge. Historically, surgery or radiotherapy represented the major treatment options. Recently, hedgehog inhibitors and checkpoint inhibitors have demonstrated significant activity. The optimal sequencing of these approaches is not yet known. We describe a case of laBCC that recurred after definitive radiotherapy. This patient was treated with neoadjuvant cemiplimab with minimal response. Cautious addition of vismodegib with ongoing cemiplimab treatment was well tolerated and resulted in significant tumor regression. A wide excision demonstrated a pathologic complete response. Further evaluation of cemiplimab and hedgehog inhibitor combination therapy in la BCC appears warranted. |
| format | Article |
| id | doaj-art-4e36e3eea7284f388fbae4fb696779e9 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-4e36e3eea7284f388fbae4fb696779e92025-01-30T06:22:03ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.15007851500785Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapyChalette Lambert-Swainston0Wolfram Samlowski1Wolfram Samlowski2Wolfram Samlowski3Brandon Reynolds4Amin Hedayat5Amin Hedayat6Kirk Kerkorian School of Medicine, Department of Internal Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV, United StatesKirk Kerkorian School of Medicine, Department of Internal Medicine, University of Nevada Las Vegas (UNLV), Las Vegas, NV, United StatesComprehensive Cancer Centers of Nevada, Las Vegas, NV, United StatesDepartment of Internal Medicine, University of Nevada School of Medicine, Reno, NV, United StatesReynolds Plastic Surgery, Las Vegas, NV, United StatesQuest Diagnostics, Associated Pathologists Chartered, Las Vegas, NV, United StatesAmerican Melanoma Institute, Las Vegas, NV, United StatesLocally advanced basal cell carcinoma (laBCC) remains a significant management challenge. Historically, surgery or radiotherapy represented the major treatment options. Recently, hedgehog inhibitors and checkpoint inhibitors have demonstrated significant activity. The optimal sequencing of these approaches is not yet known. We describe a case of laBCC that recurred after definitive radiotherapy. This patient was treated with neoadjuvant cemiplimab with minimal response. Cautious addition of vismodegib with ongoing cemiplimab treatment was well tolerated and resulted in significant tumor regression. A wide excision demonstrated a pathologic complete response. Further evaluation of cemiplimab and hedgehog inhibitor combination therapy in la BCC appears warranted.https://www.frontiersin.org/articles/10.3389/fonc.2025.1500785/fullhedgehog inhibitorcheckpoint inhibitortargeted therapyimmunotherapykeratinocyte carcinoma |
| spellingShingle | Chalette Lambert-Swainston Wolfram Samlowski Wolfram Samlowski Wolfram Samlowski Brandon Reynolds Amin Hedayat Amin Hedayat Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy Frontiers in Oncology hedgehog inhibitor checkpoint inhibitor targeted therapy immunotherapy keratinocyte carcinoma |
| title | Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| title_full | Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| title_fullStr | Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| title_full_unstemmed | Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| title_short | Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| title_sort | case report complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy |
| topic | hedgehog inhibitor checkpoint inhibitor targeted therapy immunotherapy keratinocyte carcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1500785/full |
| work_keys_str_mv | AT chalettelambertswainston casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT wolframsamlowski casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT wolframsamlowski casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT wolframsamlowski casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT brandonreynolds casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT aminhedayat casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy AT aminhedayat casereportcompleteresponseofrecurrentlocallyadvancedbasalcellcarcinomafollowingadditionofvismodegibtoneoadjuvantcemiplimabtherapy |